MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pumped to Take Bigger Share of Diabetes Market

Pumped to Take Bigger Share of Diabetes Market
The insulin pump market is a challenging, but Insulet Corp. (Bedford, MA) hasn’t let that stop it from becoming a driving force of innovation in its respective space.


“We are confident that the easy-to-use design of our tubeless insulin pump will raise the bar for the industry again and improve our competitive position in the marketplace," says Duane DeSisto, president and CEO of Insulet.

The insulin pump market is a challenging, but Insulet Corp. (Bedford, MA) hasn’t let that stop it from becoming a driving force of innovation in its respective space. With a focus on Type I diabetes, the company holds more than 7% of the underpenetrated U.S. pump market, according to Brian Roberts, the company’s CFO. Its award-winning product, the OmniPod, is the only tubeless insulin pump on the market and is used by more than 25,000 patients.
In 2010, Insulet celebrated its 10th anniversary with an aggressive international expansion for which the company anticipates reaping the benefits during the next couple of years. In May 2011, the company filed a 510(k) application for its next-generation OmniPod insulin pump and hopes to get FDA clearance by the end of this year. "The next-generation OmniPod is a third smaller, 25% lighter and is expected to reduce our cost of production by about a third, driving significant gross margin improvement,” said Duane DeSisto, president and CEO of Insulet, during a recent investor conference call. The company reengineered some of the materials used to manufacture the device and removed some expensive components to achieve a 65%+ margin profile. For example, the device uses three batteries instead of four, and the semiconductor chip was simplified—all while offering the same benefits as its predecessor.
Nearly 1.4 million people in the United States have Type 1 diabetes, and one out of four patients use insulin pumps. The OmniPod, which has been available for five years, is by far simplest and most easy-to-use pump on the market, said Roberts. The device provides enough insulin to be worn for three full days and strips out complexities of conventional diabetes products.
The company generated 36% more revenue
in Q1 2011 than it did in Q1 2010.
Insulet's most promising patient population is the under-18 age group, which is the OmniPod’s fastest growing segment. Currently, 30% of the company’s customer base is under 18. Roberts is confident that this particular patient population won't ever use a conventional pump. “That group’s never going to leave the iPod and go back to the cassette player,” he said.
The other advantage for Insulet’s expansion is the growing U.S. diabetes market, which is expected to achieve a compound annual growth rate of 10%, according to the World Health Organization. Roberts anticipates that the U.S. insulin pump market will double in its share of the type I diabetes market by 2018. The company could be preparing to meet this growing need. Last year it produced more than 4 million OmniPods, and this year, it expects to manufacture about 7 million. “We’re positioned as the wave of the future to be the pump of choice,” said Roberts.
Focus Going Forward
  • Anticipate clearance of next-generation OmniPod in Q4 2011.
  • Begin to see return on investment from aggressive international expansion during the next few years.
Insulet’s gross profit for Q1 2011 represented
a 48% gross margin.
  • June 2011: Acquires Neighborhood Diabetes Inc. for $63 million.
  • March 2011: Signs agreement with GlaxoSmithKline Inc. to distribute OmniPod in Canada.
  • October 2010: Ranked third fastest-growing company in North America on Deloitte LLP’s Technology Fast 500 list.
  • September 2010: Diabetes Therapy publishes an article stating that the OmniPod is an improvement upon existing conventional insulin delivery products.
  • September 2009: Names second fastest –growing company in Massachusetts by The Boston Business Journal.
  • July 2009: Establishes Eco-Pod program to encourage environmentally safe disposal of insulin pump components.
  • Duane DeSisto, president, CEO, and director
  • Brian Roberts, CFO
  • Charles Liamos, COO
  • Peter Devlin, chief commercial officer
  • R. Anthony Diehl, general counsel
Insulet Corp. prides itself on how the OmniPod provides patients with a high level of insulin management. Animas Corp. makes the OneTouch and Medtronic makes the MiniMed.
Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.